ClinicalTrials.gov
public full text
Public Domain
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D#804785
- The Effects of Rifaximin Therapy in Irritable Bowel Syndrome#1096268
- Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders#838058
- Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.#845665
- Induction of Clinical Response Using Rifaximin in Crohn's Disease#1075107
Record · ID 826879
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive